Gene · 54386
TERF2IP: TERF2 interacting protein
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. TERF2IP: TERF2 interacting protein. Genes, record 54386. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/54386
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q9NYB0 | Telomeric repeat-binding factor 2-interacting protein 1 | 399 | 5 | Ensembl, GeneID, HGNC |
Source UniProt
Patents23
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4704859 A1 | 2026-03-11 | 1 | Q9NYB0 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 3980 | Q9NYB0 | Espacenet |
| EP 4640849 A2 | 2025-10-29 | 516 | Q9NYB0 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 3561 | Q9NYB0 | Espacenet |
| JP 2025519096 A | 2025-06-24 | 516 | Q9NYB0 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 3561 | Q9NYB0 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 3980 | Q9NYB0 | Espacenet |
| JP 2024123008 A | 2024-09-10 | 8632 | Q9NYB0 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 87589 | Q9NYB0 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 190560 | Q9NYB0 | Espacenet |
1 to 10 of 23
See all 23 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,134
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | TERF2IP papers | Newest fiscal year |
|---|---|---|---|
| R01AG016642 | Mechanism of the telomeric proliferation limit | 18 | 2025 |
| P30CA125123 | Baylor College of Medicine Cancer Center - Cancer Center Support Grant | 9 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 8 | 2025 |
| ZIACP010190 | Genetic Epidemiology of Telomere Maintenance and Cancer Etiology | 7 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 6 | 2025 |
| P30ES009089 | Center for Environmental Health in Northern Manhattan | 6 | 2025 |
| P30CA014195 | Cancer Center Support Grant (CCSG) | 5 | 2025 |
| P30ES025128 | Center for Human Health and the Environment (CHHE) | 5 | 2025 |
| R35CA210036 | Genome instability in cancer: telomeres and DNA repair | 5 | 2025 |
| ZIACP004410 | Family Studies | 5 | 2025 |
1 to 10 of 1,134Source NIH's project files
See all 1,134 nih grantsPapers1,658
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| DHODH inhibition drives albumin-mediated drug resistance through TERF2IP lactylation-activated macropinosome-mitochondria contact. | Nat Commun | 2026 | 42736281 | PubTator, text mining | PubMed |
| Non-Telomeric Role of RAP1 in Facilitating NF-κB Activation and Driving Hepatocellular Carcinoma Progression. | IUBMB Life | 2026 | 42458663 | PubTator, text mining | PubMed |
| The Role of Genetics in Malignant Melanoma: A Comprehensive Review. | Surg Clin North Am | 2026 | 42419313 | PubTator, text mining | PubMed |
| Prevalence of Familial Melanoma Genes and Cancer Risk Among Genomically Ascertained Individuals. | JAMA Dermatol | 2026 | 42201696 | PubTator, text mining | PubMed |
| Structural basis for TRF2-RAP1 recruitment by EBNA1 at the EBV origin of replication. | Sci Rep | 2026 | 41957069 | PubTator, text mining | PubMed |
| TRF2-RAP1 inhibits homology-directed repair of telomeres by promoting BLM-mediated removal of telomere R-loops. | Nucleic Acids Res | 2026 | 41914496 | PubTator, text mining | PubMed |
| Micronuclei: origins, assays, mechanisms, diseases and treatments. | Signal Transduct Target Ther | 2026 | 41888103 | PubTator, text mining | PubMed |
| Machine learning identifies a DNA repair-related risk model for bladder cancer and functionally characterizes ZWINT as a potential oncogenic factor. | Transl Androl Urol | 2026 | 41809788 | PubTator, text mining | PubMed |
| DAB2IP: unifying cardiovascular pathogenesis and cardiovascular brain crosstalk. | Front Cardiovasc Med | 2026 | 41798622 | PubTator, text mining | PubMed |
| Exosome-delivered bioactive molecules regulate macrophage polarization in atherosclerosis and myocardial infarction: mechanisms and therapeutic potential. | Front Cardiovasc Med | 2026 | 41798608 | PubTator, text mining | PubMed |
1 to 10 of 1,658
See all 1,658 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/54386
GET https://conductscience.org/api/genes/v1/54386/patents?page=2